Lan Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lan Kong has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Derek C. Angus
University of Pittsburgh, Pittsburgh, PA
1 shared publication Eric B Milbrandt
1 shared publication- Eric B. Milbrandt
Assistant Professor, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication G. G. Koch
Department of Biostatistics , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina , USA
1 shared publicationGary G. Koch
Department of Biostatistics , University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA
1 shared publicationGary Koch
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1 shared publication
Latest Publications
- 1 August 2011
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 39 (8) , 1871-1878
Understanding the potential role of statins in pneumonia and sepsis*
Objective: To examine the association of statin use with clinical outcomes and circulating biomarkers in community-acquired pneumonia and sepsis. Design: Multicenter inception cohort study. Setting: Emergency departments of 28 U.S. hospitals. Patients: A total of 1895 subjects hospitalized with community-acquired pneumonia. Interventions: None. Measurements and Main Results: Our approach consisted of two different comparison cohorts, each reflecting methods used in prior publications in this area. We first compared subjects with prior statin use (prior use cohort), defined as a history of statin use in the week before admission, with those with no prior use. We then compared prior statin users whose statins were continued inhospital (continued use cohort) with those with either no prior use or no inhospital use. We adjusted for patient characteristics, including demographics, comorbid conditions, and illness severity, and accounted for healthy user effect and indication bias using propensity analysis. We determined risk of severe sepsis and 90-day mortality. We measured markers inflammation (tumor necrosis factor, interleukin-6, interleukin-10), coagulation (antithrombin, factor IX, plasminogen activator inhibitor, d-dimer, thrombin antithrombin complex), and lymphocyte cell surface protein expression during the first week of hospitalization. There were no differences in severe sepsis risk between statin users and nonusers for prior (30.8% vs. 30.7%, p = .98) or continued statin use (30.2% vs. 30.8%, p = .85) in univariate analyses and after adjusting for patient characteristics and propensity for statin use. Ninety-day mortality was similar in prior statin users (9.2% vs. 12.0%, p = .11) and lower in continued statin users (7.9% vs. 12.1%, p = .02). After adjusting for patient characteristics and propensity for statin use, there was no mortality benefit for prior (odds ratio, 0.90 [0.63–1.29]; p = .57) or continued statin use (odds ratio, 0.73 [0.47–1.13]; p = .15). Only antithrombin activity over time was higher in statin subjects, yet the magnitude of the difference was modest. There were no differences in other coagulation, inflammatory, or lymphocyte cell surface markers. Conclusions: We found no evidence of a protective effect for statin use on clinical outcomes and only modest differences in circulating biomarkers in community-acquired pneumonia, perhaps as a result of healthy user effects and indication bias.
- 1 August 2011
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 39 (8) , 1871-1878
Understanding the potential role of statins in pneumonia and sepsis*
Objective: To examine the association of statin use with clinical outcomes and circulating biomarkers in community-acquired pneumonia and sepsis. Design: Multicenter inception cohort study. Setting: Emergency departments of 28 U.S. hospitals. Patients: A total of 1895 subjects hospitalized with community-acquired pneumonia. Interventions: None. Measurements and Main Results: Our approach consisted of two different comparison cohorts, each reflecting methods used in prior publications in this area. We first compared subjects with prior statin use (prior use cohort), defined as a history of statin use in the week before admission, with those with no prior use. We then compared prior statin users whose statins were continued inhospital (continued use cohort) with those with either no prior use or no inhospital use. We adjusted for patient characteristics, including demographics, comorbid conditions, and illness severity, and accounted for healthy user effect and indication bias using propensity analysis. We determined risk of severe sepsis and 90-day mortality. We measured markers inflammation (tumor necrosis factor, interleukin-6, interleukin-10), coagulation (antithrombin, factor IX, plasminogen activator inhibitor, d-dimer, thrombin antithrombin complex), and lymphocyte cell surface protein expression during the first week of hospitalization. There were no differences in severe sepsis risk between statin users and nonusers for prior (30.8% vs. 30.7%, p = .98) or continued statin use (30.2% vs. 30.8%, p = .85) in univariate analyses and after adjusting for patient characteristics and propensity for statin use. Ninety-day mortality was similar in prior statin users (9.2% vs. 12.0%, p = .11) and lower in continued statin users (7.9% vs. 12.1%, p = .02). After adjusting for patient characteristics and propensity for statin use, there was no mortality benefit for prior (odds ratio, 0.90 [0.63–1.29]; p = .57) or continued statin use (odds ratio, 0.73 [0.47–1.13]; p = .15). Only antithrombin activity over time was higher in statin subjects, yet the magnitude of the difference was modest. There were no differences in other coagulation, inflammatory, or lymphocyte cell surface markers. Conclusions: We found no evidence of a protective effect for statin use on clinical outcomes and only modest differences in circulating biomarkers in community-acquired pneumonia, perhaps as a result of healthy user effects and indication bias.
- 17 March 2009
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 65 (1) , 135-142
Case–Cohort Analysis with Accelerated Failure Time Model
Summary In a case–cohort design, covariates are assembled only for a subcohort that is randomly selected from the entire cohort and any additional cases outside the subcohort. This design is appealing for large cohort studies of rare disease, especially when the exposures of interest are expensive to ascertain for all the subjects. We propose statistical methods for analyzing the case–cohort data with a semiparametric accelerated failure time model that interprets the covariates effects as to accelerate or decelerate the time to failure. Asymptotic properties of the proposed estimators are developed. The finite sample properties of case–cohort estimator and its relative efficiency to full cohort estimator are assessed via simulation studies. A real example from a study of cardiovascular disease is provided to illustrate the estimating procedure.
- 17 March 2009
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 65 (1) , 135-142
Case–Cohort Analysis with Accelerated Failure Time Model
Summary In a case–cohort design, covariates are assembled only for a subcohort that is randomly selected from the entire cohort and any additional cases outside the subcohort. This design is appealing for large cohort studies of rare disease, especially when the exposures of interest are expensive to ascertain for all the subjects. We propose statistical methods for analyzing the case–cohort data with a semiparametric accelerated failure time model that interprets the covariates effects as to accelerate or decelerate the time to failure. Asymptotic properties of the proposed estimators are developed. The finite sample properties of case–cohort estimator and its relative efficiency to full cohort estimator are assessed via simulation studies. A real example from a study of cardiovascular disease is provided to illustrate the estimating procedure.
- 1 August 2006
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 16 (4) , 555-572
Design of Vaccine Equivalence/Non-Inferiority Trials with Correlated Multiple Binomial Endpoints
Immunogenicity trials that study the immune responses to vaccination are often used in the vaccine development process as alternatives to clinical efficacy trials. The comparisons of immune responses among various treatment groups are conducted in a non-inferiority or equivalence framework. When there exists a level of immune response that correlates with protection against disease, it is of interest to compare the proportion of responders as defined as response above a specific level or as a predefined increase in immune levels for post-vaccination levels above pre-vaccination levels. Since vaccines often contain several antigens, the correlations between the immune responses need to be taken into account in the analysis. In this paper, we describe appropriate testing methods for demonstrating the non-inferiority/equivalence of two treatments on each of the binomial endpoints. We conduct a comprehensive simulation study to shed light on how the Type I error and power are affected and to what extent when correlated multiple binomial endpoints are present in the vaccine trials. We also illustrate the computation of power for assessment of non-inferiority/equivalence in real studies.
- 1 August 2006
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 16 (4) , 555-572
Design of Vaccine Equivalence/Non-Inferiority Trials with Correlated Multiple Binomial Endpoints
Immunogenicity trials that study the immune responses to vaccination are often used in the vaccine development process as alternatives to clinical efficacy trials. The comparisons of immune responses among various treatment groups are conducted in a non-inferiority or equivalence framework. When there exists a level of immune response that correlates with protection against disease, it is of interest to compare the proportion of responders as defined as response above a specific level or as a predefined increase in immune levels for post-vaccination levels above pre-vaccination levels. Since vaccines often contain several antigens, the correlations between the immune responses need to be taken into account in the analysis. In this paper, we describe appropriate testing methods for demonstrating the non-inferiority/equivalence of two treatments on each of the binomial endpoints. We conduct a comprehensive simulation study to shed light on how the Type I error and power are affected and to what extent when correlated multiple binomial endpoints are present in the vaccine trials. We also illustrate the computation of power for assessment of non-inferiority/equivalence in real studies.
- 1 January 2005
- Published by Wiley in Pharmaceutical Statistics
- Vol. 4 (1) , 25-35
Performance of some multiple testing procedures to compare three doses of a test drug and placebo
- 1 January 2005
- Published by Wiley in Pharmaceutical Statistics
- Vol. 4 (1) , 25-35
Performance of some multiple testing procedures to compare three doses of a test drug and placebo
- 31 December 2004
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 14 (4) , 893-907
Type I Error and Power in Noninferiority/Equivalence Trials with Correlated Multiple Endpoints: An Example from Vaccine Development Trials
Clinical trials necessary for the development of new treatment often require testing of multiple endpoints for equivalence or noninferiority relative to an existing effective standard therapy. An example is a vaccine study with multiple antibody measurements in sera of subjects receiving a combination vaccine such as a pneumococcal vaccine, which contains many different serotypes of the pneumococcal organism. This article describes testing methods for the demonstration of simultaneous marginal equivalence or noninferiority of two treatments on each component of the response vector that follows a multivariate normal distribution. Systematic simulation studies are conducted to evaluate the performance of the testing method and to examine under what conditions the power is substantially different if the multiple endpoints are assumed to be independent when they are actually strongly correlated. Data from an illustrative example are used to describe how the study power can be evaluated in the design of the trials.
- 31 December 2004
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 14 (4) , 893-907
Type I Error and Power in Noninferiority/Equivalence Trials with Correlated Multiple Endpoints: An Example from Vaccine Development Trials
Clinical trials necessary for the development of new treatment often require testing of multiple endpoints for equivalence or noninferiority relative to an existing effective standard therapy. An example is a vaccine study with multiple antibody measurements in sera of subjects receiving a combination vaccine such as a pneumococcal vaccine, which contains many different serotypes of the pneumococcal organism. This article describes testing methods for the demonstration of simultaneous marginal equivalence or noninferiority of two treatments on each component of the response vector that follows a multivariate normal distribution. Systematic simulation studies are conducted to evaluate the performance of the testing method and to examine under what conditions the power is substantially different if the multiple endpoints are assumed to be independent when they are actually strongly correlated. Data from an illustrative example are used to describe how the study power can be evaluated in the design of the trials.
- 1 October 2004
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 10 (5) , 391-394
Advances in statistical methodology and their application in critical care
To review some of the major advances in statistical methodology of the past two decades and their application to investigations in critical care. The introduction of new technologies and the ready availability of advanced computer resources have led to significant developments in statistical methodology. These include the development of computationally intensive methods, improved methods for modeling correlated outcome data, and new methods for handling missing data. Although many of these tools are available in standard statistical software, they remain underutilized in the medical literature. By becoming familiar with advances in statistical methodology, researchers and clinicians can enhance collaboration with their statistical colleagues, toward the goal of better study design and analysis.
- 1 October 2004
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 10 (5) , 391-394
Advances in statistical methodology and their application in critical care
To review some of the major advances in statistical methodology of the past two decades and their application to investigations in critical care. The introduction of new technologies and the ready availability of advanced computer resources have led to significant developments in statistical methodology. These include the development of computationally intensive methods, improved methods for modeling correlated outcome data, and new methods for handling missing data. Although many of these tools are available in standard statistical software, they remain underutilized in the medical literature. By becoming familiar with advances in statistical methodology, researchers and clinicians can enhance collaboration with their statistical colleagues, toward the goal of better study design and analysis.